ClearPoint Neuro has revised its 2026 revenue guidance to between $48 million and $52 million, down from the prior range of $52 million to $56 million, as it shifts investment toward clinical readiness, its CAL preclinical facility, and a focused ultrasound partnership. President and CEO Joseph Burnett said faster partner regulatory timelines have elevated the need for commercial readiness activities, prompting the company to prioritize clinical case support, global regulatory expansion, and development of focused ultrasound robotics and Harmony software over traditional sales expansion. The company reported second-quarter 2026 revenue of $10.9 million with a gross margin of 62%, while cash and cash equivalents stood at $29.4 million as of June 30, 2026, reflecting an operational cash burn of $15 million through the first half of the year. CFO Danilo D’Alessandro noted that biologics and drug delivery revenue fell 15% to $4 million, neurosurgery navigation revenue grew to $5.6 million, and capital equipment and software revenue increased 24% to $1.3 million. Management expects operational cash burn to decrease in the second half as the IRRAS integration completes, and Burnett expressed confidence in scaling, citing more than 30 trained clinical specialists and a new CAL facility that could surpass $60 million in annual capacity.
Clearpoint Neuro IncCompany lowers 2026 revenue guidance, indicating reduced growth expectations.